Monash IVF Group (MVF.AX) Stock Price
Monash IVF Group Price
Revenue has compounded at 8.2% per year over the past 16 years to 269.46 M AUD. Earnings per share have grown at 4.6% per year over the last 12 years. Monash IVF Group's net margin stands at 2.8%, down from 9.6% several years earlier. Monash IVF Group currently offers a dividend yield of about 1.63%. The payout ratio is around 102% of earnings. Analysts set a median price target of 0.86 AUD, implying 16.6% above the current price. Of 10 analysts, 6 rate the stock a buy — an overall Buy consensus.
Monash IVF Group stock price
Monash IVF Group business model & stock analysis
Frequently asked questions about Monash IVF Group
Monash IVF Group Ltd is primarily active in the healthcare and biotechnology industries.
Some of the main competitors of Monash IVF Group Ltd in the market include Virtus Health Limited, Healthscope Limited, and Genea Limited. These companies also operate in the fertility services sector and compete with Monash IVF Group Ltd in providing reproductive and infertility treatments.
Monash IVF Group Ltd operates as a leading fertility provider in Australia. The company's business model focuses on offering a comprehensive range of assisted reproductive services. Monash IVF Group specializes in fertility treatments, including in vitro fertilization (IVF), sperm and egg donation, genetic testing, and surrogacy. With a dedicated team of specialists and advanced laboratory facilities, Monash IVF Group aims to help individuals and couples achieve their dream of having a family. By combining cutting-edge technology, personalized care, and research advancements, the company strives to deliver the highest quality fertility care to its patients.
Monash IVF Group Ltd, founded in 2000, is a leading Australian fertility services provider. Specializing in assisted reproductive technology and treating infertility, the company has a rich history of pioneering advancements. Monash IVF Group Ltd operates a network of fertility clinics, offering comprehensive services such as in vitro fertilization, fertility testing, and sperm and egg donation. With a team of highly skilled specialists, the company is committed to delivering exceptional patient care and achieving strong success rates in fertility outcomes. Monash IVF Group Ltd has grown to become a trusted name in the fertility industry, consistently providing hope and support to individuals and couples seeking to start or expand their families.
Monash IVF Group Ltd has achieved several significant milestones. The company has a strong track record of delivering high success rates in assisted reproductive technologies such as in vitro fertilization (IVF) and has assisted in the birth of over 30,000 babies. Monash IVF Group Ltd has also pioneered innovative fertility treatments and technologies, including the development of genetic testing for embryos and advancements in egg freezing techniques. The company's commitment to research and clinical excellence has made them a leading player in the fertility industry, earning them a reputation for delivering exceptional patient outcomes and maintaining a position at the forefront of reproductive medicine.
Monash IVF Group Ltd primarily operates in Australia and Malaysia. Australia is its main market, where it has multiple clinics located across the country. Additionally, the company has a significant presence in Malaysia, offering fertility services through its strategic partnership with Sunfert International. Monash IVF Group Ltd's focus on these countries and regions allows it to provide comprehensive reproductive and fertility services to patients, including in vitro fertilization (IVF), genetic testing, and other related treatments.
Monash IVF Group Ltd represents values of excellence, innovation, and patient-centered care. With a corporate philosophy focused on fulfilling the dreams of parenthood, Monash IVF Group Ltd is dedicated to providing cutting-edge fertility treatments and personalized support to couples and individuals. By leveraging its extensive experience and technological advancements, the company strives to deliver superior reproductive medicine services. Monash IVF Group Ltd maintains its commitment to the highest ethical standards, transparency, and fostering a compassionate and inclusive environment for its patients.
Analysts currently set an average price target of 0.85 AUD for the Monash IVF Group stock (median: 0.86 AUD), implying +15.2 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the Monash IVF Group stock: 6 recommend buying, 4 holding and 0 selling.
Converted at the current exchange rate, the Monash IVF Group share trades at 0.45 EUR (0.74 AUD).
The Monash IVF Group share (MVF.AX) is listed on 3 stock exchanges, including: ASX (MVF.AX), Frankfurt (MIS.F), München (MIS.MU).
Monash IVF Group Ltd is an Australian-based company that specializes in providing assisted reproductive technology (ART) and the investigation and treatment of infertility. The company currently operates multiple fertility clinics and laboratories in Australia and New Zealand. The company offers a wide range of reproductive and fertility services that focus on meeting the specific needs and requirements of each customer. This includes in-vitro fertilization (IVF), intrauterine insemination (IUI), sperm and egg donation, as well as preimplantation diagnosis (PID) and genetic testing. Monash IVF Group has also specialized in researching and developing new technological approaches for assisted reproduction. This includes an extensive research program that focuses on investigating factors that influence fertility, such as lifestyle factors, environmental influences, and genetic predispositions. Another important aspect of the company is the education of doctors, nurses, and other professionals in assisted reproduction. Monash IVF Group offers a variety of courses, training, and workshops to constantly improve and develop knowledge and skills in the field of assisted reproductive technologies. In addition to its clinical services and research program, Monash IVF Group also operates its own diagnostic laboratory that offers a wide range of tests for diagnosing infertility. This includes hormone analysis, semen analysis, and genetic testing. The company is also able to extend its services to international customers. Monash IVF Group has a strong presence in Asia and currently operates clinics in Malaysia and Singapore. Overall, Monash IVF Group has a comprehensive business model that focuses on providing high-quality reproductive and fertility services, conducting innovative research programs, educating professionals, and expanding international markets. The company is well-positioned to grow its customer base and expand its range of services and products to meet the changing demands in the field of assisted reproductive technology.
The revenue of Monash IVF Group is 269.46 M AUD. This figure is based on current financial data and reflects the company's business performance.
The profit of Monash IVF Group is 7.43 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Monash IVF Group is currently 38.57. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Monash IVF Group stock.
The price-to-sales ratio (P/S) of Monash IVF Group is currently 1.06. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Monash IVF Group stock.
The Eulerpool Quality Score for Monash IVF Group is 3/10.
The ISIN of Monash IVF Group is AU000000MVF3. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Monash IVF Group is A116LZ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Monash IVF Group is MVF.AX. The ticker symbol is used to trade Monash IVF Group shares on the stock exchange.
Monash IVF Group stock
Monash IVF Group Peer Group
Monash IVF Group Ticker
Monash IVF Group FIGI
All fundamentals and in-depth analysis of Monash IVF Group
Our stock analysis for Monash IVF Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Monash IVF Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.